Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients
- 1 February 2018
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 63, 116-121
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethalityBlood, 2013
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesBlood, 2013
- MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent mannerBlood, 2013
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic MelanomaClinical Cancer Research, 2013
- The Mammalian Target of Rapamycin: Linking T Cell Differentiation, Function, and MetabolismImmunity, 2010
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsJournal of Experimental Medicine, 2009
- Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature reviewMedical Oncology, 2009
- Simultaneous suppression of MITF and BRAFV600E enhanced inhibition of melanoma cell proliferationCancer Science, 2009
- Impairment of CD4+CD25+ regulatory T-cells in autoimmune liver diseaseJournal of Hepatology, 2004
- Skin Cancers after Organ TransplantationNew England Journal of Medicine, 2003